Clinical Trial Detail

NCT ID NCT03631407
Title Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

colorectal cancer

Therapies

Pembrolizumab + Vicriviroc

Age Groups: senior adult

No variant requirements are available.